ArticleBMC medical imaging2025
Clinical application of radiofrequency echographic multi-spectrometry (REMS) for diagnosis and follow-up in several rare bone disorders: a case series.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Radiofrequency Echographic Multi-Spectrometry (REMS) for Bilateral Femoral Neck Assessment in Pregnant Women: A Cross-Sectional Study.Life (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Radiofrequency Echographic Multi Spectrometry (REMS) is a portable and radiation-free technology that can evaluate and monitor osteoporosis. In particular, REMS has been shown to measure bone mineral density (BMD) at axial skeletal bones with a precision, repeatability and accuracy not inferior to those of dual-energy X-ray absorptiometry (DXA). Moreover, REMS may be useful in the assessment of impaired bone quality and to predict fragility fracture risk. Due to these characteristics, REMS could be usefully used in the diagnosis and follow up of osteoporosis in rare bone diseases. The clinical cases includes in this study were selected among those that best highlight the strengths of REMS technology. A recent study conducted on subjects affected by osteogenesis imperfecta has demonstrated that the REMS technique is able to assess BMD in the same way as the DXA evaluation. REMS has also demonstrated excellent diagnostic accuracy in some patients suffering from others rare disease such as McCune-Albright or Ehlers-Danlos syndromes. Furthermore, REMS could be particularly advantageous in children and in women of childbearing age or during pregnancy and breastfeeding. In conclusion, on the basis of these preliminary data, REMS can be usefulness for the evaluation and monitoring of bone in individuals with rare bone diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.